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Important factors known to, or are suspected of influencing outcomes in stage IIB include histological type, tumour volume and haemoglobin level during therapy. Treatment-related factors include CRT versus radiation alone, minimizing overall treatment time, and total radiation doses to Point A. 5 A positive Human Immunodeficiency Virus (HIV) status, especially if untreated with antiretroviral therapy, has a deleterious effect on outcome after CRT and increases acute epithelial side effects within the radiation volume. 6, 7 There are remaining questions about how best to administer concurrent chemotherapy. In the case of CRT with weekly cisplatin, the literature does not give detailed guidance on the cumulative drug dose required for optimal benefit. The number of weekly concurrent cisplatin cycles may also impact outcomes; Nugent et al. conducted a retrospective analysis of the effect of the number of cycles completed with radiotherapy in 118 patients and found that fewer than five cycles were associated with reduced survival rates when compared with five or six cycles. 8 The optimal day of the week for the administration of concurrent cisplatin has not been investigated. Potentially, administering chemotherapy during the early part of the week could increase the interaction of drug and radiation when compared administration later in the week. This is a retrospective clinical audit of 228 patients with stage IIB cervical cancer treated with curative intent over a 15-year period at a single institution. The study examines the impact of several factors on patient survival to establish priorities for optimizing outcomes.
METHODS:
Institutional ethics approval was obtained (HREC 832/2014). Patient informed consent for data assembly and analyses was not required due to the retrospective nature of this study with anonymous data handling. Data were extracted for all patients with FIGO stage IIB cervical cancer registered during 1995-2010 at the Groote Schuur Hospital, Cape Town, South Africa. Inclusion criteria included: proven histological diagnosis of squamous, adeno-squamous or adenocarcinoma of the uterine cervix; receiving external beam radiotherapy (EBRT) dose of at least 45 Gy to the whole pelvis; receiving two-to-four sessions of brachytherapy (BT); and receiving one-to-six weekly cycles of concurrent cisplatin (40 mg/m 2 , capped at 60 mg per week). Data were extracted for selected tumour and treatment-related factors and the HIVstatus was recorded. Tumour volume was measured as cervical diameter in cm, determined from CT images or clinical palpation, while involvement of parametria and vagina were determined clinically. Individual patient haemoglobin (HB) values were expressed as the average weekly levels during treatment (AWHB in g/dL). Pre-treatment values were not recorded. Treatment duration was measured from the first to the last day of radiation, regardless of whether the last exposure was from EBRT or BT, and it is reported as Overall Treatment Time (OTT) in days. Total radiation doses to Point A were expressed as the summation of EBRT and BT doses, as expressed by Linear Quadratic Equivalent Dose to 2 Gy per fraction (LQED2). Radiation on the day of cisplatin administration was given within two hours, either before or after chemotherapy.
Analysis was conducted using Prism v6.05 (GraphPad Software Inc., San Diego, California). Numerical variables were summarized by means, or dichotomized at various cut-off points and compared with the log-rank test for the outcome of survival. Categorical variables were summarized by frequencies and percentages. Survival was estimated using the Kaplan-Meyer method, with differences between groups assessed by the log-rank method. Overall survival (OS) was defined as extending from the first day of treatment to death from any cause, otherwise censored at the date of last patient contact. Other time-to-event outcomes were not considered because follow-up intervals were variable over the study period. Statistical significance was defined as p-value < 0.05. Multivariable Cox regression model with proportional hazards was used to assess the independent significance of potential predictive factors for the outcome of OS.
RESULTS:
Of 410 patients with stage IIB cervical cancer managed between 1995 and 2010, 228 met the criteria for inclusion in the study (see figure 1) . Patient, disease and treatment characteristics are presented (Table I ). Table I .
EBRT was administered with four portals in 160 patients, anterior-posterior in 60, while eight patients received extended field radiation for suspicious para-aortic lymph nodes (1. Most cisplatin cycles were administered on Thursdays because of logistical considerations within the department. Two thirds of patients received either five or six cycles of weekly cisplatin.Where receiving fewer cycles, administrative or scheduling issues were responsible in 32% of instances, mostly failure to start cisplatin during the first week of RT. In the remainder, deterioration of the weekly white cell to <2.5 10 9 /L, platelet count to <75,000 10 9 /L, or an increase in serial creatinine measurements, were responsible for delaying or suspending chemotherapy; these reasons are regarded as unpreventable. Chemotherapy was not delayed for low HB levels. A total of 15.5% of patients declined to complete all the cycles because of nausea or personal reasons.
Overall survival for all patients was 60% at five years. There was no significant influence on OS for: age; whether the cisplatin was administered on Mondays or Thursdays; tumour volume differences; total LQED2 to Point A; and HIV-positive or negative status (all HIVpositive patients received antiretroviral therapy). Variables found to be significant for differences in OS were: weekly cisplatin for six as compared with one to five cycles (p<0.026); six as compared with five cycles (p<0.01); squamous vs non-squamous histology (p<0.003); AWHB at cut-off level >10.0 (p<0.032); and OTT with cut-off 45 days (p<0.03). By Cox regression, on multivariate analysis only squamous histology, AWHB >10 g/dL, and weekly cisplatin of six cycles (Table II, This study surveyed which tumour or treatment parameters appear to influence overall survival, and which could potentially be managed to maximize treatment outcomes. The study found only the following factors to be significantly associated with a better OS on multivariate analysis: six cycles of weekly cisplatin, an AWHB of >10.0 g/dL during CRT, and squamous histology.
Non-squamous pathology
Squamous histology conferred a better prognosis in the present study. Yokio et al. (2017), 9 in a retrospective survey of patients with locally advanced disease had similar findings; 9.6% of their cohort had adenocarcinoma or adeno-squamous histology and did significantly worse than patients with squamous tumours. The authors recommended that a specific CRT regimen be developed for non-squamous histologies.
Concurrent chemotherapy
Cisplatin-based concurrent chemo-radiation has become the established curative treatment worldwide for cervical cancer.
10
The preferred regimen is weekly cisplatin during EBRT, because of the relative convenience of outpatient administration and fewer side effects than other schedules. The weekly dosage established in two of the five originator randomized studies was cisplatin 40mg/m 2 , with capping at 70 mg absolute weekly dose in one of the two studies using this regimen.
11,12 A meta-analysis of pooled individual patient data has found a 7% absolute improvement in 5-year OS for stage IIB with CRT vs. RT alone (and only 3 % in stage IIIB).
13
Three studies warrant mention because the benefit of CRT over RT alone could not be demonstrated; Chen et al. reported a control-cohort retrospective study which included 171 patients with stages IIB and IIIB, of whom 80% completed five cycles of weekly cisplatin (40 mg/m 2 , capped at 60 mg/week). 14 This is a dose regimen similar to the one used in the current study, and perhaps six cycles are required at this dosage, as suggested by our findings. A randomized study from Canada included substantial numbers if stage IIB patients. Seventy percent of patients completed the planned five cycles (40mg/m 2 without capping). The reasons given for the failure to show benefit for CRT in this study included: the study was underpowered, more anaemia in the CRT arm, and/or higher RT doses in the RT-alone arm than used in the American studies of CRT. 15 In another randomized trial, conducted by the International Atomic Energy Agency, 601 patients with IIB/IIIBcervical cancer received either RT or CRT -66% completed 5 weekly cycles of cisplatin. Cancer-specific survival was of marginal significance (p = 0.078, but intention-to-treat p = 0.2). 16 The optimal dose of cisplatin has also not been well defined. 21 Whether this a function of cumulative dose, or of a larger number of cycles giving optimum radiosensitization, are uncertain.
Alternative strategies to improve chemotherapy delivery include a finding by Ruy et al in an RCT in which the standard weekly regimen was compared to cisplatin 75 mg/m 2 every three weeks for three cycles: survival rates were better, and side effects fewer, in the three-weekly arm. 22 Weekly CRT with carboplatin (Area Under Curve = 2) is another apparently equipotent option, with less morbidity according to a randomized study of cisplatin vs carboplatin in locally advanced disease, reported by Tharvichitkul et al., (2016). 23 Lastly, efforts to reduce treatment toxicity could improve tolerance. Intensity Modulated Radiotherapy (IMRT) was recently studied in locally advanced disease by Mell and co-workers, 24 with the hypothesis that a reduction in radiation exposure to bowel and functioning bone marrow would improve tolerability to CRT. Compared to historical data, a significant decrease in gastrointestinal and haematological side effects was seen, and 82% of patients could complete five or more cycles of cisplatin at 40mg/m 2 without dose capping.
The present study did not demonstrate any difference in outcome between Monday or Thursday administration of concurrent cisplatin. Although patient numbers were small, it is more likely that any benefit effect of Monday administration, with potentially more interaction with EBRT than when given closer to the following weekend, is diminutive, or non-existent. We could not find reports in the literature which mention the day of week, except to "start CRT on day one of radiation".
Anaemia and transfusions
Anaemia in cervical cancer theoretically increases the hypoxic cell component within tumours, which would contribute to radio-resistance and poorer outcomes. 25 There is debate as to whether anemia in itself is prognostic, or whether it is the phenotype of a more aggressive underlying cancer. Low HB levels during radiotherapy may be more significant than pre-treatment levels, as first described by Dr Raymond Bush in 1986. 26 In 2009, Grogan et al., also from Canada, retrospectively studied the impact of anaemia and blood transfusion on the outcome of cervical cancer patients treated with definitive radiotherapy. 27 An intratherapy AWHB level of ≥ 12g/dL from start of treatment, or maintained during treatment with blood transfusion, was prognostic, while pre-treatment HB level was not, in a multivariate analysis. Winter et al. (2004) , in a retrospective assessment of patients treated on two consecutive Gynecology Oncology Group trials, affirmed these findings; an AWHB level ≥12g/dL during treatment was an independent predictor of disease-free experience for locally advanced disease. Reduced levels in the last part of the EBRT course were most predictive of local recurrence. 28 Kapp and co-workers (2002) concluded that red cell transfusions are beneficial, using a threshold HB of 11g/dL. Multivariate analysis, correcting for tumour size and nodal status, confirmed that only HB during treatment was significant. 29 Another retrospective study, by Obamair et al. (2000), also found that pre-treatment HB levels were not prognostic. A HB nadir of >11g/dL during CRT had a 90% chance of a complete clinical response and was significantly related to better progression-free survival. 30 In a study of 88 patients with locally advanced disease, Mayr and co-workers measured tumour perfusion using dynamic contrast enhanced magnetic resonance imaging. Patients with a combination of low tumour perfusion and AWHB <11.2 g/dL had significantly worse outcomes, suggesting synergistic negative effects. These authors recommended dual assessment of both perfusion and AWHB to guide the management of anaemia during CRT, especially in the poorly-diffusing tumours. 31 In a retrospective review of a large patient cohort, Bishop et al. (2015) questioned the relationship between low HB level and outcomes after treatment. The only significant association on multivariate analysis was that HB <10 during radiotherapy was associated with disease-specific survival. The benefit of blood transfusions was unclear from their data. 32 Fyles and colleagues from the Princess Margaret Hospital in Toronto maintained that anaemia in cervical cancer correlates with tumour size and therefore may not be independently prognostic. A randomized study of transfusion in cervical cancer, previously performed at their institution, failed to demonstrate any benefit. 33 
Overall radiation treatment time
Protracted radiation (generally defined as OTT ≥ 8 weeks), has been reported in several retrospective studies to have statistically significant associations with poor pelvic control and survival. Saibishkumar et al. 34 found the cut-off to be seven weeks, while Perez's group calculated a loss of pelvic tumour control of 0.68%/day if OTT >7 weeks in stage IIB. 35 On the contrary, Huang et al. (2016) , 36 in a study of stage IIB patients treated with uniform RT doses, high dose rate BT started after completion of teletherapy showed that OTT did not impact either survival or local recurrence, although if OTT were ≤56 days there was a negative effect on proctitis. For this reason, these authors recommended a one-week gap between teletherapy and commencing BT. Another group of investigators found that when concurrent cisplatin was added to RT, an extended OTT had no effect on treatment outcome. 37 Our finding of a significant difference in survival for OTT > 45 days on univariate analysis was not sustained on multivariate analysis. It is generally accepted, however, that prolongation of treatment should be avoided.
Other factors
Perez et al. (1992) conducted a retrospective assessment of the impact of tumour extent and size on local control and distant failure in 1,178 patients treated with definitive radiotherapy, 353 of whom had stage IIB disease. Tumours were described in terms of size (cut-off 5 cm) and anatomic extent (unilateral vs.bilateral, and medial vs. lateral parametrial involvement), reflecting intra-stage volume differences. The 10-year actuarial pelvic failure rate was significantly associated with tumour size and lateral parametrial involvement in Stage IIB. There was no difference between unilateral vs bilateral disease. Larger tumours (≥ 5cm) also had a higher incidence of distant failure and lower disease-free survival. This data predate the CRT era, however. 38 Our study did not confirm any effect of disease volume, possibly because of smaller patient numbers, or less precise recording of disease extent, than in the Perez review.
Adverse outcomes associated with HIV infection in cervical cancer patients include shorter overall survival, increased pelvic failures, and increased risk of multi-organ radiation-related acute toxicity and treatment interruption. 6, 39 Untreated HIV is also associated with anaemia, a factor with a negative influence on CRT outcome in cervical cancer. 40 Only 6.8% of the patients tested for HIV in this study were positive, which is below the current prevalence at our institution (25% in 2015 -L van Wijk, Personal communication). This is most likely due to the low prevalence and inconsistent testing during the early years of the study. The relatively small numbers of HIV-positive patients, who were all receiving antiretroviral therapy, could explain why they did not experience a worse overall survival. It is crucial, however, that newly discovered HIV infection at time of a cervical cancer diagnosis be promptly started on antiretroviral therapy prior to commencing CRT. 41 
Study limitations
Limitations inherent to this retrospective study include potential bias from inconsistent examiner-dependent assessments of tumour volume at baseline. Further, RT treatment schedules changed over the study period. Parameters such as progression-free survival, tumour responses and complication rates were deliberately not used, given the risk of detection bias from non-uniform follow-up intervals.
Conclusions
Exploring prognostic factors may identify ways to improve outcomes through modifying treatment and strengthening supportive strategies to encourage adherence to treatment. Nonsquamous cervical cancer histology might benefit from exploring other concurrent chemotherapy options (e.g. taxanes). Concurrent CRT with weekly cisplatin is the standard therapy in squamous cervical cancer but optimal scheduling and drug dosage may require further refinement. In this study of CRT in stage IIB, better survival occurred with six cycles at the dose-schedule described. The number of weekly cycles may outweigh cumulative dose of cisplatin for interaction with radiation. We aim to strengthen departmental systems to strive for the six planned administrations in all patients and to commence concurrent chemotherapy on day 1 of EBRT. Despite dose capping, patients still miss weekly cycles because of either side effects or laboratory deviations, but removing the dose cap of 60mg/week may increase delays from acute toxicity. Anaemia of AWHB £ 10.0 g/dL during CRT was a negative prognostic factor with stage IIB. While our study was not designed to examine benefit from blood transfusion, uncertainty regarding transfusion can only be resolved by a randomized trial. Our practice was to transfuse all symptomatic anaemic patients, although there is sufficient evidence in the literature to suggest that levels of >10 g/dL should be maintained during therapy; in view of this, we use oral antifibrinolytic agents liberally, and transfuse when HB is <10 g/dL.
